Featured Research

from universities, journals, and other organizations

Trial Shows Promise For Arthritis Drug

Date:
June 27, 2009
Source:
BioMed Central
Summary:
A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well-tolerated and effective. Researchers have shown that treatment with masitinib significantly reduced the severity of active arthritis.

A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective. Researchers writing in BioMed Central's open access journal Arthritis Research and Therapy have shown that treatment with masitinib significantly reduced the severity of active arthritis.

Olivier Hermine worked with researchers from several French hospitals to carry out this trial in 43 patients with arthritis resistant to current treatments. He said, "In choosing which interventions to use for the management of rheumatoid arthritis, it is important to recognise that treatment should aim to keep the disease in remission and not be used intermittently to manage exacerbations. We are encouraged from this study that masitinib not only appears to be effective, but that within the first 3 months of treatment the worst of its side-effects were over, possibly making it suitable for long-term treatment regimens". He adds, "The results of this study also help establish the critical role of mast cells in the pathogenesis of rheumatoid arthritis and demonstrate their viability as a therapeutic target. There is sufficient compelling evidence to warrant further placebo-controlled investigation".

Masitinib inhibits the activity of mast cells, a component of the immune system thought to be involved in the pathogenesis of rheumatoid arthritis. The clinical improvement described in the study was supported by laboratory evidence of reduced inflammation. The authors found that adverse effects of the treatment were mainly mild to moderate.

Alain Moussy from AB Science, a pharmaceutical company who are developing masitinib for multiple indications in human and animal medicine said, "This is a milestone article for us, being the first publication of masitinib in a human study". Speaking about the drug, Alain Moussy said, "Our preclinical studies have shown that masitinib selectively targets cell receptors known to be involved in various disease processes but does not affect those associated with toxicity, particularly cardiotoxicity".

Rheumatoid arthritis is a chronic autoimmune condition which causes systemic inflammation, particularly affecting the joints. The ultimate cause remains unknown. The disease affects women more often than men and the prevalence rated is estimated to be 1%.

Masitinib is already approved by EMEA and under registration review with FDA for canine mast cell tumours (trade name Masivetฎ). The drug is also in numerous phase II/III clinical trials, including further arthritis related studies, which are intended to fully exploit its potential therapeutic benefits over a wide range of cancers, inflammatory diseases, and neurological indications.


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jacques Tebib, Xavier Mariette, Pierre Bourgeois, Ren้-Marc Flipo, Philippe Gaudin, Xavier Le Lo๋t, Paul Gineste, Laurent Guy, Colin D Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine and Jean Sibilia. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Research & Therapy, (in press) [link]

Cite This Page:

BioMed Central. "Trial Shows Promise For Arthritis Drug." ScienceDaily. ScienceDaily, 27 June 2009. <www.sciencedaily.com/releases/2009/06/090626190933.htm>.
BioMed Central. (2009, June 27). Trial Shows Promise For Arthritis Drug. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2009/06/090626190933.htm
BioMed Central. "Trial Shows Promise For Arthritis Drug." ScienceDaily. www.sciencedaily.com/releases/2009/06/090626190933.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins